CG Oncology

Today we are proud to announce the initiation of our Expanded Access Program (EAP) for cretostimogene grenadenorepvec in the U.S. for patients with Non-Muscle Invasive Bladder Cancer (#NMIBC) who are unresponsive to Bacillus Calmette-Guerin (BCG) and meet certain program eligibility criteria. The first patient has been dosed in the EAP, and enrollment is ongoing. 📄 Read the full release here: https://bit.ly/3Rv5a7C Healthcare providers and bladder cancer patients who are interested to learn more about CG Oncology’s EAP including eligibility criteria may visit www.clinicaltrials.gov, NCT06443944, or contact EAP@cgoncology.com. #BladderCancer #ClinicalTrials #UroOncology #Immunotherapy #PatientCare #DrugDevelopment #Immunotherapy #Therapeutics #CGOncology #cretostimogene

Today, CG Oncology announced Nature Medicine's publication of phase 1b study results evaluating cretostimogene grenadenorepvec in combination with nivolumab in Muscle-Invasive Bladder Cancer, as well as the simultaneous presentation at the Society for Immunotherapy of Cancer 2024. The encouraging data adds to the body of evidence supporting the potential use of cretostimogene as a backbone bladder-sparing therapeutic for bladder cancer. Check out the release here: https://lnkd.in/eFgRnRZH

The Bladder Cancer Advocacy Network recently held a Summit in Philadelphia where members of the Bladder Cancer community including patients, care givers, health care providers and members of industry came together. Over the course of the two day meeting we learned about BCAN's innovations in bladder cancer support, heard expert advice on navigating survivorship and nurturing urinary and bladder health post-treatment, and learned about advancements in bladder cancer research. We also had the opportunity to speak with many patients about their journeys with bladder cancer, which underscored the importance of new treatment options. Thank you to BCAN for convening such a meaningful forum and welcoming us to participate. -with Elaine Harris, Kristen M., Andrea Maddox-Smith and Sarah Connors

CG Oncology is excited to announce & welcome our newest additions to the team: Chau Cheng - Vice President, Investor Relations Daytriona Clemons, PharmD - Clinical Trials Scientist Abhishek Sharma - Sr. Director, Health Economics & Outcomes Research Anvita Valluru - Sr. Associate, CMC Strategy & Submissions Wesley Williams, PhD - Sr. Scientist, Materials, Science & Technology Marian Escobar - Accounts Payable Specialist Aman D. - Director, Talent Acquisition & Total Rewards Gay Gauvin - Associate Vice President, Technical Operations Karen To - Associate Director, Clinical Supply Chain

Our team enjoyed connecting with urologists and healthcare professionals from across the globe at the 44th Congress of the Société Internationale d'Urologie. Thanks to #SIU2024NewDelhi for the opportunity to provide updates on CG Oncology's investigational, intravesically delivered oncolytic immunotherapy, cretostimogene grenadenorepvec, and to Drs Piyush Agarwal, Sia Daneshmand, M.D., Sarah Psutka MD MSc, Mark Tyson, M.D., M.P.H for sharing the latest data as part of six 'Trial in Progress' presentations! -with Vijay Kasturi and Ambaw Bellete

At the 2024 International Bladder Cancer Network Annual Meeting in Bern Switzerland, Dr. Colin Dinney, MD Anderson Cancer Center, presented the first translational research for the BOND-003 Phase 3 Study evaluating cretostimogene grenadenorepvec, CG Oncology's investigational oncolytic immunotherapy in BCG-unresponsive #NMIBC. Thank you to Dr. Dinney for sharing this data at such an important global forum for the urology community. We also appreciate UroToday covering Dr. Dinney's presentation and urge you to check it out: https://lnkd.in/gTYpAtWC

Are you ready to make a difference in the world and become part of our patient-centered team that is focused on attacking bladder cancer for a better tomorrow? The CG Oncology team is growing fast and we recently passed 100 employees. We have a number of job openings for passionate and talented professionals. Check them out here: https://lnkd.in/e-UiUYdg

Members of our Leadership Team as well as our Medical and Clinical Teams are proud to participate in the European Society of Medical Oncology Congress, #ESMO24, this week in Barcelona. Our team is excited to learn about the latest advances in oncology research and to engage with clinicians, researchers, patient advocates, and other members of the global oncology community. We are inspired by the shared commitment to patients suffering with cancer. 

Members of our Medical and Clinical Teams recently attended the Mid-Atlantic Sectional and New England Sections AUA meetings. The team enjoyed hearing about the latest advancements in urology and engaging with urologists, residents and other members of the urology community about CG Oncology's pipeline and ongoing clinical trials. Thanks to Vijay Kasturi, Shelja Patel, PharmD, RPh, BCMAS, Annie Shafiq, PharmD, MS, Anthony Fernandez, PharmD, MSL-BC, and Sarah Weyandt for representing CG Oncology!